 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123 |
- | VAC18193 / J&J
Trial completion: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Feb 19, 2019
P1, N=73, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed
- | VAC18193 / J&J
Trial completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Feb 19, 2019
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Trial completion date: Jun 2020 --> Oct 2020
- | VAC18193 / J&J
Trial primary completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jan 23, 2019
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Jun 2020 --> Oct 2020 Trial primary completion date: Nov 2019 --> Jun 2020
- | VAC18193 / J&J
Enrollment open: A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults (clinicaltrials.gov) - Jan 23, 2019
P1, N=24, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Nov 2019 --> Jun 2020 Not yet recruiting --> Recruiting
- | VAC18193 / J&J
New P1 trial: A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults (clinicaltrials.gov) - Jan 7, 2019
P1, N=24, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- | VAC18193 / J&J
Trial completion: An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (clinicaltrials.gov) - Dec 5, 2018
P2a, N=64, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | VAC18193 / J&J
Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Nov 28, 2018
P1/2, N=667, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Trial primary completion date: Oct 2018 --> Apr 2021
- | VAC18193 / J&J
Trial completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Nov 7, 2018
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Oct 2018 --> Apr 2021 Trial completion date: Jan 2020 --> Jun 2020
- | VAC18193 / J&J
Phase classification: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Sep 20, 2018
P1/2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Jan 2020 --> Jun 2020 Phase classification: P2 --> P1/2
- | VAC18193 / J&J
Trial completion, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Sep 5, 2018
P2a, N=180, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Phase classification: P2 --> P1/2 Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Jul 2018
- | VAC18193 / J&J
Enrollment closed, Enrollment change: An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (clinicaltrials.gov) - Aug 17, 2018
P2a, N=64, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Jul 2018 Recruiting --> Active, not recruiting | N=44 --> 64
- | VAC18193 / J&J
Phase classification: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Aug 16, 2018
P2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting | N=44 --> 64 Phase classification: P1/2 --> P2
- | VAC18193 / J&J
New P1/2 trial, New P2 trial: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jul 31, 2018
P1/2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- | VAC18193 / J&J
Enrollment open: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Jul 19, 2018
P1/2, N=562, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Phase classification: P1/2 --> P2 Not yet recruiting --> Recruiting
- || VAC18193 / J&J
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jun 20, 2018
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Trial completion date: Aug 2019 --> Nov 2019 | Trial primary completion date: Aug 2019 --> Nov 2019
- || VAC18193 / J&J
Trial completion date, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Aug 2019 --> Nov 2019 | Trial primary completion date: Aug 2019 --> Nov 2019 Trial completion date: Mar 2019 --> Aug 2019
- ||||| VAC18193 / J&J
New P1/2 trial: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=562, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- ||| VAC18193 / J&J
Enrollment closed: A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Feb 28, 2018
P2a, N=180, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Mar 2019 --> Aug 2019 Recruiting --> Active, not recruiting
- ||| VAC18193 / J&J
Enrollment change, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jan 16, 2018
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting N=48 --> 60
- | VAC18193 / J&J
Phase classification, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jan 16, 2018
P1/2, N=60, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
N=48 --> 60 Phase classification: P2 --> P1/2
- |||| VAC18193 / J&J
Enrollment open: A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Dec 18, 2017
P2a, N=180, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Phase classification: P2 --> P1/2 Not yet recruiting --> Recruiting
- | VAC18193 / J&J
Enrollment open, Phase classification, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Dec 6, 2017
P2, N=48, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P2
- VAC18193 / J&J
Phase classification, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Nov 14, 2017
P1/2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P2 Phase classification: P2 --> P1/2
- ||||| VAC18193 / J&J
New P2a trial: A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Nov 13, 2017
P2a, N=180, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- || VAC18193 / J&J
Enrollment closed: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Nov 8, 2017
P1, N=73, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Phase classification: P2 --> P1/2 Recruiting --> Active, not recruiting
- | VAC18193 / J&J
New P2a trial: An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (clinicaltrials.gov) - Nov 7, 2017
P2a, N=44, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- VAC18193 / J&J
Phase classification, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Nov 4, 2017
P2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P2
- | VAC18193 / J&J
New P2 trial, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Oct 9, 2017
P2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- | VAC18193 / J&J
New P1/2 trial, IO biomarker: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Oct 5, 2017
P1/2, N=48, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- || VAC18193 / J&J
Trial primary completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - May 25, 2017
P1, N=72, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Phase classification: P1/2 --> P2 Trial primary completion date: Mar 2019 --> Feb 2018
- ||| VAC18193 / J&J
Enrollment open: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Dec 4, 2016
P1, N=72, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Mar 2019 --> Feb 2018 Not yet recruiting --> Recruiting
- ||| VAC18193 / J&J
New P1 trial: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (clinicaltrials.gov) - Oct 5, 2016
P1, N=72, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.